"Centre hospitalier régional - public toutes spécialités médicales et chirurgicales 24H/24 Urgences et SAMU - consultations - imagerie - laboratoires."

During the past decade, CHR ORLEANS - Hématologie conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHR ORLEANS - Hématologie" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Janssen-Cilag Ltd." with 2 trials as a collaborator, "Acute Leukemia French Association" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "BeiGene" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "CHR ORLEANS - Hématologie" are "Acute Myeloid Leukemia" (3 trials), "CLL/SLL" (1 trials), "Fit Patients" (1 trials), "Intermediate Risk Chronic Lymphocytic Leukemia" (1 trials) and "Myeloproliferative Syndrome" (1 trials). Many other conditions were trialed in "CHR ORLEANS - Hématologie" in a lesser frequency.

Most popular intervention types in "CHR ORLEANS - Hématologie" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "ACA Continuation" (1 trials), "CPX-351" (1 trials), "Cytarabine-Idarubicin Association" (1 trials), "Cytarabine-Venetoclax Association" (1 trials) and "Dexamethasone" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHR ORLEANS - Hématologie" are 6 trials for "All" genders.

Currently, there are NaN active trials in "CHR ORLEANS - Hématologie". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in CHR ORLEANS - Hématologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHR ORLEANS - Hématologie, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".